Enlivex, a cell immunotherapy
company, is developing an autologous and allogeneic drug pipeline for the treatment of autoimmune
and inflammatory conditions such as Graft versus Host Disease (GvHD), solid
organ transplant rejection, and Crohn’s disease.
Our revolutionary approach to
inducing immune tolerance utilizes apoptotic cells to activate the body's
innate, physiologic mechanism for down-regulating inflammation and